Drugs / MVA-EbolaZ
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02408913 | Mar 2015 → Apr 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02368119 | Mar 2015 → Sep 2016 | Ebola hemorrhagic fever | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT02354404 | Jan 2015 → Apr 2017 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-EbolaZ | “VRC-EBOMVA079-00-VP (MVA-EbolaZ)” NCT02408913 ↗ |
| Known as | VRC-EBOMVA079-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02408913 ↗ |
| Modality | Vaccine | “IM injection of MVA-EbolaZ vaccine” NCT02368119 ↗ |
| Route | Intramuscular | “IM injection of MVA-EbolaZ vaccine” NCT02368119 ↗ |